Effects of potassium channel opener KRN4884 on human conduit arteries used as coronary bypass grafts

British Journal of Clinical Pharmacology

Volumn 50, Issue 2, 2000, Pages 154-160

  Ren, Zhen ^a,b   Floten, Storm ^a,b   Furnary, Anthony ^a,b   Liu, Minghui ^a,b   Gately, Hugh ^a,b   Swanson, Jeffrey ^a,b   Ahmad, Aftab ^a,b   Yim, Anthony P C ^a,b   He, Guo Wei ^a,b,c  

^a PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Human conduit arteries; KRN4884; Potassium channel opener; Vasorelaxation

Indexed keywords

5 AMINO N [2 (2 CHLOROPHENYL)ETHYL] N' CYANO 3 PYRIDINECARBOXAMIDINE; ANGIOTENSIN; ENDOTHELIN 1; GLIBENCLAMIDE; NORADRENALIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; SEROTONIN;

ADULT; AGED; ARTICLE; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MAMMARY ARTERY; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION; VASOCONSTRICTION; VASOSPASM;

AGED; ANALYSIS OF VARIANCE; CONFIDENCE INTERVALS; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAMMARY ARTERIES; MIDDLE AGED; POTASSIUM CHANNELS; PYRIDINES; VASODILATION; VASODILATOR AGENTS;

EID: 0033858646     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00235.x     Document Type: Article

References (42)

1. 1 Cooper GJ, Wilkinson GAL, Angelini GD. Overcoming perioperative spasm of the internal mammary artery: Which is the best vasodilator? J Thorac Cardiovasc Surg 1992; 104: 465-468.
2. 2 He G-W, Yang C-Q, Mack MJ, Acuff TE, Ryan WH. Starr a. Interaction between endothelin and vasodilators in the human internal mammary artery. Br J Clin Pharmacol 1994; 38: 505-512.
3. 3 He G-W, Yang C-Q. Inhibition of vasoconstriction by phosphodiesterase III inhibitor milrinone in human conduit arteries used as coronary bypass grafts. J Cardiovasc Pharmacol 1996; 28: 208-214.
4. 4 ACC,/AHA. Guidelines for the early management of patients with acute myocardial infarction. Circulation 1990; 82: 667.
5. 5 He G-W, Yang C-Q. Inhibition of vasoconstriction by potassium channel opener aprikalim in human conduit arteries used as bypass grafts. Br J Clin Pharmacol 1997; 44: 353-359.
6. 6 Lazdunski M. ATP-sensitive potassium channels: an overview. J Cardiovasc Pharmacol 1994; 24: S1-S5.
7. 7 Cook NS. The pharmacology of potassium channels and their therapeutic potential. Trends Pharmacol Sci 1988; 9: 21-28.
8. 8 Quast U, Guillon JM, Cavero O. Cellular pharmacology of potassium channel openers in vascular smooth muscle. Cardiovasc Res 1994; 28: 805-810.
9. 2+ concentration and mechanical activity induced by noradrenaline in the rabbit mesenteric artery. Br J Pharmacol 1991; 104: 227-233.
10. 2+ sensitivity of arterial smooth muscle. Arch Int Pharmacodyn 1993; 326: 33-51.
11. 11 Izumi H, Jinno Y, Kaneta S, et al. Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipne, and nifedipine. J Cardiovasc Pharmacol 1995; 26: 189-197.
12. + channel opener, KRN4884, and related compounds in porcine coronary artery. Gen Pharmacol 1996; 27: 985-989.
13. 13 He G-W, Angus JA, Rosenfeldt FL. Reactivity of the canine isolated internal mammary artery, saphenous vein, and coronary artery to constrictor and dilator substances: Relevance to coronary bypass graft surgery. J Cardiovasc Pharmacol 1988; 12: 12-22.
14. 14 He G-W, Baxton B, Rosenfeld F, Angus JA. Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Implications for treatment of internal mammary artery spasm. Circulation 1989; 80(Suppl): I-141-I-150.
15. 15 Sarab MR, McClung JA, Fass A, Reed GR. Early postoperative spasm in left internal mammary artery bypass grafts. Ann Thorac Surg 1987; 44: 199-200.
16. 16 Loop FD, Thomas JD. Hypoperfusion after arterial bypass grafting. Ann Thorac Surg 1993; 56: 812-813.
17. 17 Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass mechanisms involved and possible therapeutic strategies. Chest 1997; 112: 676-692.
18. 18 He G-W, Yang C-Q, Starr A. Overview of the nature of vasoconstriction in arterial grafts for coronary operation. Ann Thorac Surg 1995; 59: 676-683.
19. 19 Downing SW, Edmunds LH. Release of vasoactive substance during cardiopulmonary bypass. Ann Thorac Surg 1992; 104: 465-468.
20. 20 Shinbo A, Ono K, Iijma T. Activation of cardiac ATP-sensitive K + channels by KRN4884, a novel K + channel opener. J Pharmacol Exp Ther 1997; 283: 770-777.
21. 21 Kawahara JI, Izumi H, Okada Y, Izawa T. Effects of the potassium channel openers KRN4884 and levcromakalim on the contraction of rat aorta induced by A23187, compared with nifedipine. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 354: 460-465.
22. 22 Izumi H, Kawahara J, Takeuchi A, Izawa T, Ogawa N. In vitro and in vivo vasodilating effects of KRN4884, Ki1769 and Ki3005, pyridinecarboxamidine derivatives. Fundam Clin Pharmacol 1997; 11: 561-566.
23. 23 Brophy CM, Awolesi M, Sumpio BE. Regulation of vasomotor tone and vasospasm. In The Basic Science of Vascular Disease eds Sidaway AN, Sumpio BE, Depakma RG. NY. Futural Publishing Company, Inc.; 367-384, 1997.
24. 24 Yanagisawa M, Kurihawa H, Kimura S, et al. A novek potent vasoconstrictor peptide produced by vascular endothelial cell. Nature (Lond.) 1998; 332: 411-415.
25. 25 Haynes WG. Endothelins as regulators of vascular tone in man. Clin Sci 1995; 88: 509-517.
26. 2+ channel in vascular smooth muscle. Proc Natl Acad Sci USA 1989; 86: 3915-3918.
27. 27 de Aguilera EM, Irurzun A, Vila JM, Aldasoro M, Liuch S. Role of endothelium and calcium channels in endothelin-induced contraction of human cerebral arteries. Br J Pharmacol 1990; 99: 439-440.
28. 28 Ohlstein EH, Horohonich S, Hay DWP. Cellular mechanisms of endothelin in rabbit aorta. J Pharmacol Exp Ther 1989; 250: 548-555.
29. 29 He G-W, Yang C-Q, Mack MJ, Acuff TE, Ryan WH, Starr A. Interaction between endothelin and vasodilators in the human internal mammary artery. Br J Clin Pharmacol 1994; 38: 505-512.
30. + channels and depolarizes smooth muscles cells of porcine coronary artery. Circ Res 1992; 70: 612-616.
31. 31 Haynes WG, Webb DJ. Venoconstriction to endothelin-1 in human: role of calcium and potassium channels. Am J Physiol (Heart Circ Physiol) 1993; 265: H1676-1681.
32. 32 Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci 1993; 84: 485-500.
33. + efflux and vasorelaxation induced by P1075, a K (ATP) channel opener, in rat isolated aorta. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 425-432.
34. + channel openers and blocked by artidiabetic sulfonylureas. Proc Natl Acas Sci USA 1991; 88: 5438-5442.
35. 35 Akar F, Uydes-Dogan BS, Tufan HA, Slamaci S, Koksoy C, Kanzik I. The comparison of the responsiveness of human isolated internal mammary and gastroepiploic arteries to levcromakalim: an alternative approach to the management of graft spasm. Br J Clin Pharmacol 1997; 44: 49-56.
36. 36 Lawson K, Barras M, Zazzi-Sudriez E, Martin DJ, Armstrong JM, Hicks PE. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers. Br J Pharmacol 1992; 107: 58-65.
37. ATP) openers in models of myocardial ischemia and reperfusion. Can J Physiol Pharmacol 1997; 75: 309-315.
38. 38 Gross GJ. ATP-sensitive potassium channels and myocardial preconditioning. Basic Res Cardiol 1995; 90: 85-88.
39. 39 Kirsch M, Baufreton C, Fernandaz C, et al. Preconditioning with cromakalim improves long-term myocardial preservation for heart transplatation. Ann Thorac Surg 1998; 66: 417-424.
40. 40 He G-W, Yang C-Q. Superiority of hyperpolarizing to depolarizing cardioplegia on the EDHF-mediated relaxation. J Thorac Cardiovasc Surg 1997; 114: 643-650.
41. 41 He G-W. Potassium channel opener in cardioplegia may restore coronary endothelial function. Ann Thorac Surg 1998; 66: 1318-1322.
42. 42 Yokoyama T, Izumi H, Endoh M, Ogawa N, Izawa T, Okada Y. Effect of KRN4884 on lipid metablism in hyperlipidemic rats. Gen Pharmacol 1998; 30: 233-237.